shu-508 and Ovarian-Cysts

shu-508 has been researched along with Ovarian-Cysts* in 2 studies

Trials

1 trial(s) available for shu-508 and Ovarian-Cysts

ArticleYear
Visualization of blood flow in small ovarian tumor vessels by transvaginal color Doppler sonography after echo enhancement with injection of Levovist.
    Gynecologic and obstetric investigation, 1994, Volume: 38, Issue:3

    The echo-enhancing effect of an ultrasound contrast medium (Levovist) in color Doppler sonography of small vessels in ovarian tumors was studied in a group of 30 women. The vascularity of adnexal masses with a suspicion of primary carcinoma in 3 and benign lesions in 27 cases was investigated before and after injection of 300 mg/ml of Levovist. In 17 cases color flow mapping showed increased vascularity either in the cystic wall or in solid structures within the tumor. In all patients we observed enhancement of Doppler signal intensity. Our results show that Levovist facilitates waveform analysis in very small vessels with poor velocity patterns.

    Topics: Adnexal Diseases; Adult; Aged; Female; Humans; Injections, Intravenous; Middle Aged; Ovarian Cysts; Polysaccharides; Regional Blood Flow; Ultrasonography, Doppler, Color

1994

Other Studies

1 other study(ies) available for shu-508 and Ovarian-Cysts

ArticleYear
Contrast-enhanced sonography in the examination of benign and malignant adnexal masses.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2000, Volume: 19, Issue:11

    Our objective was to characterize the properties of an intravascular ultrasonographic contrast agent in examination of adnexal masses and to compare contrast agent properties between benign and malignant adnexal tumors. Fifty-eight consecutively examined women with suspected ovarian tumors were examined preoperatively by power Doppler ultrasonography, first without and then with contrast agent enhancement (Levovist). Fourteen women had ovarian cancer, 3 had borderline ovarian tumors, 18 had benign ovarian neoplasms, and 23 had functional adnexal cystic masses or endometriomas. The effect of the contrast agent was evaluated visually and by using computerized power Doppler signal intensity measurements. In visual evaluation, the brightness of the power Doppler signal and the amount of recognizable vascular areas increased in each tumor after contrast agent administration. The number of vessels in power Doppler ultrasonograms, both before and after contrast agent enhancement, was significantly higher in malignant than in benign adnexal masses, as also was the increase in the number of recognizable vessels after contrast agent administration. Contrast agent uptake time was significantly shorter in malignant than in benign tumors. No significant differences were found in the power Doppler signal intensities or their changes between benign and malignant tumors. In conclusion, use of sonographic contrast agent facilitates imaging of tumor vessels. For differentiation of benign and malignant tumors, the kinetic properties of the contrast agent, such as uptake and washout times, may have more potential than the use of the contrast agent in anatomic imaging of the tumor vessels.

    Topics: Abscess; Adenofibroma; Adnexal Diseases; Adult; Aged; Aged, 80 and over; Contrast Media; Cystadenoma; Dermoid Cyst; Endometriosis; Fallopian Tube Diseases; Female; Humans; Image Enhancement; Middle Aged; Ovarian Cysts; Ovarian Diseases; Ovarian Neoplasms; Polysaccharides; Ultrasonography, Doppler

2000